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ABSTRACT
In the world of pain, we must always consider
the presence of gender. In nociception, as well
as in pain, women are different from men in
many, if not all, aspects of the system. Noci-
ception is the sum of several events that occur
from the periphery to the CNS, and there is
much evidence that female nociception differs
from male nociception. Moreover, it has to be
considered that pain results from a male or a
female cortex. Genetic, anatomical, physiolog-
ical, hormonal, psychological, and social factors
have been considered to explain the differences
present at both levels. Notwithstanding all the
evidence, it is still difficult to observe the
application of this knowledge to the treatment
of pain. Drugs are still given per kilogram, and
clinical studies, albeit including women, often
mix data from both sexes. Moreover, reports on
these studies often fail to mention the women’s
age and reproductive status, i.e., sex hormones.
Hormone levels vary from hour to hour, from
day to day, and, as repeatedly confirmed, are
affected by several pain killers commonly used
in pain therapy. All the data confirm the urgent
need to include sex differences and sex hor-
mones among the key factors that play an
important role in pain and pain treatment.
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EDITORIAL
Pain is divided into acute and chronic. Acute
pain is an alarm system able to preserve the
individual’s health status. Chronic pain is an
illness that may be disconnected from the
original pathology and without any meaning
for the subject. Sex differences have been found
in both conditions.
Acute experimental pain, in which the
painful stimulus is short-lasting and the
threshold and tolerance are the studied param-
eters, often presents sex differences depending
on the painful stimulus used to test the patient,
with women being equally or more affected
than men [1].
Chronic pain is not one pathology but
hundreds. Chronic pain can affect all parts of
the body, with different features related to the
quality, intensity, time course, and clinical
outcome. These pathologies include many
chronic painful syndromes that are more com-
mon in women, while others are more common
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in men and others still have a similar incidence
in the two sexes [2]. This simple evidence sug-
gests that there is no common pathophysio-
logical sex-related mechanism underlying all
painful conditions; any one condition is mod-
ulated by factors that could differ between men
and women.
It is known that when pain is related to a
clinical condition that can be painful (e.g.,
diabetes) the incidence is due to the primary
pathology. Interestingly, also in this case it is
quite difficult to find studies regarding the rel-
ative incidence of pain in the different diseases;
e.g., given the same number of diabetic
patients, is pain more common in men or
women?
To explain the higher incidence in women in
some chronic painful syndromes, it has been
hypothesized that the female anatomical fea-
tures, mostly related to pelvic organs, could
play an important role [3]. The female bladder is
much more exposed to external pathogens than
the male bladder on account of the shorter
urethral tract and the vagina connecting the
external environment directly with the interior
of the pelvis. The colon could be inflamed—ir-
ritable bowel syndrome (IBS) and other forms of
colitis are more common in women [4].
All these conditions can be painful per se or
merely able to lower the threshold of other
painful conditions. Indeed they are often pre-
sent at the subclinical level and subjects are not
aware of the inflammation processes occurring
in one or more pelvic viscera; pain, if present, is
often referred to other parts of the soma, e.g., to
the back.
Sex hormones are important modulators of
body functions. We know their role in repro-
duction, but often we forget that androgen and
estrogen have receptors in almost all cells of our
body; their action can be rapid or slow but in
any case it can be important for the functioning
of many systems, including nociception/pain.
Only recently, attention has been focused on
the action of sex hormones on pain modulation
and in particular on the immune system. For
instance, microglia, the resident immune cells
in the CNS, play a critical role (different in men
and women) in the pathogenesis of chronic
pain, particularly in the development of central
sensitization and neuropathic pain [5]. Of
course, sex differences in microglia are just one
aspect of the broader male–female differences in
the immune system.
Another important interaction between sex
hormones and the pain system regards the
endogenous and/or exogenous opioid system.
The arcuate nucleus of the hypothalamus is the
main site of b-endorphin production. Its axons
end in the periaqueductal gray matter (PAG)
where the release of b-endorphin is able to
activate the descending inhibitory pathways.
The b-endorphin neurons in the arcuate
nucleus are strongly modulated by estrogens
[6]. Furthermore, many studies have reported
that the spinal d and j opioid antinociceptive
systems are functionally associated with estro-
gens. In particular, estrogen receptors regulate
synthesis and secretion of the d opioid receptor
ligand methionin-enkephalin in addition to the
well-known regulation of b-endorphin content
and secretion [7].
In an interesting experiment, male and
female mice used to replicate a model of neu-
ropathic pain showed that the two sexes react
differently to structural and functional changes
induced by sciatic nerve ligature. While the
male mice showed a gradual decrease of allo-
dynia and a complete recovery from the injury,
in the female mice the allodynia and gliosis
were still present 4 months after induction of
neuropathy. Estrogen supplementation was able
to attenuate this difference, reducing the allo-
dynia and inducing a complete recovery also in
the female mice [8].
Thus, although estrogens are clearly
involved in pain modulation, their role is still
not clear. Estrogens remain a complex
‘‘world’’—from the great difficulty in measuring
them to their complex hypothalamic-pituitary
modulation, their enzymatic production (aro-
matase enzyme and others), and their complex
receptor system (both at the cytoplasm and
membrane levels) [9]. For all these reasons, it
took a long time to realize that estrogen
administration to experimental animals could
induce opposite results depending on many
factors, a major one being the concentration. In
pain modulation, all kinds of results were
found: to summarize we can say that low
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estrogen concentrations generally have a
pronociceptive action while higher concentra-
tions can have an important analgesic effect, as
occurs during pregnancy [10].
In conclusion, these few experimental results
explain the need to maintain the focus on sex
differences in pain and on sex hormones, since
they are powerful molecules able to influence
all the cells of our body. Their multi-target
interaction with CNS functions allows contin-
uous reciprocal modulation. Mood, arousal,
learning, and memory are all modulated by sex
hormones directly and/or indirectly, e.g.,
through the immune system; these processes
are all involved in pain modulation.
Therefore, hormonal fluctuations due to
reproductive cycles, life events, and pharmaco-
logical treatments are important. This variabil-
ity can be significant, i.e., it can improve or
worsen body conditions, but it is important to
consider that these changes can also be induced
artificially. Sex hormones, like all hormones,
can be given or blocked: why not do this for
pain?
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